Strides receives USFDA approval for Amantadine Hydrochloride capsules
To be marketed by Strides Pharma Inc. in the US market
To be marketed by Strides Pharma Inc. in the US market
They will commercialize molnupiravir in the international markets
The company has 271 cumulative ANDA filings with USFDA of which 243 ANDAs have been approved and 28 are pending approval
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
The company has started manufacturing the Sputnik Light vaccine
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
The company expects revenue growth of 10-15 per cent in the US
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
He will be stationed at the company HQ in Bengaluru, India
Subscribe To Our Newsletter & Stay Updated